| 中國醫藥大學 |
2002-03-24 |
Pelvic Lipomatosis：A Case Report and Review of Literature
|
(吳紘岳); 陳國樑; 吳錫金(Wu,Hsi-Chin) |
| 臺北醫學大學 |
2013 |
Pelvic retroperitoneal cyst during pregnancy: A case report
|
Chen, CH;Lin, JY;Chiu, LH;Liu, WM |
| 臺北醫學大學 |
2013 |
Pelvic retroperitoneal cyst during pregnancy: A case report
|
CH, Chen;JY, Lin;LH, Chiu;WM, Liu |
| 臺大學術典藏 |
2018-09-10T08:22:21Z |
Pelvic skeletal metastasis of hepatocellular carcinoma with sarcomatous change: A case report
|
Chen, C.-Y. and Hsueh, Y.-T. and Lan, T.-Y. and Lin, W.-H. and Wu, K. and Yang, R.-S.; WEI-HSIN LIN; RONG-SEN YANG |
| 臺大學術典藏 |
2010 |
Pelvic skeletal metastasis of hepatocellular carcinoma with sarcomatous change: A case report
|
WEI-HSIN LIN; Lan T.-Y.; Hsueh Y.-T.; Chen C.-Y.; Yang R.-S.; Wu K. |
| 臺大學術典藏 |
2021-05-31T02:57:19Z |
Pelvic skeletal metastasis of hepatocellular carcinoma with sarcomatous change: A case report
|
Chen C.-Y.; Hsueh Y.-T.; Lan T.-Y.; Lin W.-H.; Wu K.; RONG-SEN YANG |
| 元智大學 |
2011-08 |
PEM Fuel Cell Diagnostic Tools, Chapter 10: Transparent cell, pp.209-230
|
Chun-Ying Hsu; Fangbor Weng |
| 國立臺灣科技大學 |
2018 |
PEM fuel cells of poly(2,5-benzimidazole) ABPBI membrane electrolytes doped with phosphoric acid and metal phosphates
|
Chiang Y.-C.; Tsai D.-S.; Liu Y.-H.; Chiang C.-W. |
| 元智大學 |
2020/10/19 |
PEM water electrolyzers with internal real-time sensing function
|
Chi-Yuan Lee; Chia-Hung Chen; Guo-Bin Jung; Yu-Xiang Zheng; Yi-Zhen Zeng |
| 元智大學 |
2020/10/19 |
PEM water electrolyzers with internal real-time sensing function
|
Chi-Yuan Lee; Chia-Hung Chen; Guo-Bin Jung; Yu-Xiang Zheng; Yi-Zhen Zeng |
| 元智大學 |
2015-12-11 |
PEM 水電解技術製超氧(O3)陽極製備法對性能之影響
|
余浚瑋; 葉佳鎮; 馬嘉慶; Guo-Bin Jung |
| 元智大學 |
2016-11-27 |
PEM 水電解製超氧技術中陽極端電解板之抗蝕層組成研究
|
李哲宇; 馬嘉慶; 余浚瑋; 連傳興; Guo-Bin Jung |
| 元智大學 |
2015-12-11 |
PEM 水電解製超氧技術中電解板之陽極觸媒分析
|
馬嘉慶; 陳杞文; 葉佳鎮; 林政隆; Guo-Bin Jung |
| 元智大學 |
2013 |
PEM 水電解製超氧發生器之研究
|
呂宥霆; You-Ting Lu |
| 元智大學 |
2017-12-01 |
PEM 水電解陽極端中添加碳材對性能之影響
|
Guo-Bin Jung; 林政隆; 余浚偉; 李哲宇; 甘旻諭 |
| 元智大學 |
2017-12-01 |
PEM 水電解陽極端中添加碳材對性能之影響
|
Guo-Bin Jung; 林政隆; 余浚偉; 李哲宇; 甘旻諭 |
| 臺大學術典藏 |
2005-07-31 |
PEM 燃料電池動態響應時間常數之理論與實驗研究(1/3)
|
陳發林; 陳發林 |
| 國立臺灣大學 |
2005-07-31 |
PEM 燃料電池動態響應時間常數之理論與實驗研究(1/3)
|
陳發林 |
| 輔英科技大學 |
2005-05-01 |
PeMADS6, a GLOBOSA/PISTILLATA-like Gene in Phalaenopsis equestris Involved in Petaloid Formation, and Correlated with Flower Longevity and Ovary Development
|
Tsai, W. C.; Lee, P. F.;Chen, H. I. ; Hsiao, Y. Y.; Wei, W. J. ; Pan, Z. J. ; Chuang, M. H. ;Kuoh, C. S. ;Chen , W. H. ; Chen, H. H. |
| 國立成功大學 |
2005-07 |
PeMADS6, a GLOBOSA/PISTILLATA-like gene in Phalaenopsis equestris involved in petaloid formation, and correlated with flower longevity and ovary development
|
Tsai, Wen-Chieh; Lee, Pei-Fang; Chen, Hong-Ie; Hsiao, Yu-Yun; Wei, Wan-Ju; Pan, Zhao-Jun; Chuang, Ming-Hsiang; Kuoh, Chang-Sheng; Chen, Wen-Huei; Chen, Hong-Hwa |
| 國立臺灣大學 |
2015 |
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
|
Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M.; 楊志新 |
| 臺大學術典藏 |
2021-03-09T06:45:59Z |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
|
Burtness B.;Harrington K.J.;Greil R.;Souli?Res D.;Tahara M.;De Castro G.;Jr, Psyrri A.;Bast? N.;Neupane P.;Bratland ?.;Fuereder T.;Hughes B.G.M.;Mes?A R.;Ngamphaiboon N.;Rordorf T.;Wan Ishak W.Z.;Ruey-Long Hong;Gonz?Lez Mendoza R.;Roy A.;Zhang Y.;Gumuscu B.;Cheng J.D.;Jin F.;Rischin D.;Lerzo G.;Tatangelo M.;Varela M.;Zarba J.J.;Boyer M.;Gan H.;Gao B.;Hughes B.;Mallesara G.;Taylor A.;Burian M.;Barrios C.H.;De Castro Junior D.O.;Castro G.;Franke F.A.;Girotto G.;Lima I.P.F.;Nicolau U.R.;Pinto G.D.J.;Santos L.;Victorino A.-P.;Chua N.;Couture F.;Gregg R.;Hansen A.;Hilton J.;Mccarthy J.;Soulieres D.;Ascui R.;Gonzalez P.;Villanueva L.;Torregroza M.;Zambrano A.;Holeckova P.;Kral Z.;Melichar B.;Prausova J.;Vosmik M.;Andersen M.;Gyldenkerne N.;Jurgens H.;Putnik K.;Reinikainen P.;Gruenwald V.;Laban S.;Aravantinos G.;Boukovinas I.;Georgoulias V.;Kwong D.;Al-Farhat Y.;Csoszi T.;Erfan J.;Horvai G.;Landherr L.;Remenar E.;Ruzsa A.;Szota J.;Billan S.;Gluck I.;Gutfeld O.;Popovtzer A.;Benasso M.;Bui S.;Ferrari V.;Licitra L.;Nole F.;Fujii T.;Fujimoto Y.;Hanai N.;Hara H.;Matsumoto K.;Mitsugi K.;Monden N.;Nakayama M.;Okami K.;Oridate N.;Shiga K.;Shimizu Y.;Sugasawa M.;Takahashi M.;Takahashi S.;Tanaka K.;Ueda T.;Yamaguchi H.;Yamazaki T.;Yasumatsu R.;Yokota T.;Yoshizaki T.;Kudaba I.;Stara Z.;Cheah S.K.;Aguilar Ponce J.;Gonzalez Mendoza R.;Hernandez Hernandez C.;Medina Soto F.;Buter J.;Hoeben A.;Oosting S.;Suijkerbuijk K.;Bratland A.;Brydoey M.;Alvarez R.;Mas L.;Caguioa P.;Querol J.;Regala E.E.;Tamayo M.B.;Villegas E.M.;Kawecki A.;Karpenko A.;Klochikhin A.;Smolin A.;Zarubenkov O.;Goh B.C.;Cohen G.;Du Toit J.;Jordaan C.;Landers G.;Ruff P.;Szpak W.;Tabane N.;Brana I.;Iglesias Docampo L.;Lavernia J.;Mesia R.;Abel E.;Muratidu V.;Nielsen N.;Cristina V.;Rothschild S.;Wang H.-M.;Yang M.-H.;Yeh S.-P.;Yen C.-J.;Soparattanapaisarn N.;Sriuranpong V.;Aksoy S.;Cicin I.;Ekenel M.;Harputluoglu H.;Ozyilkan O.;Harrington K.;Agarwala S.;Ali H.;Alter R.;Anderson D.;Bruce J.;Campbell N.;Conde M.;Deeken J.;Edenfield W.;Feldman L.;Gaughan E.;Goueli B.;Halmos B.;Hegde U.;Hunis B.;Jotte R.;Karnad A.;Khan S.;Laudi N.;Laux D.;Martincic D.;Mccune S.;Mcgaughey D.;Misiukiewicz K.;Mulford D.;Nadler E.;Nunnink J.;Ohr J.;O'Malley M.;Patson B.;Paul D.;Popa E.;Powell S.;Redman R.;Rella V.;Rocha Lima C.;Sivapiragasam A.;Su Y.;Sukari A.;Wong S.;Yilmaz E.;Yorio J.; Burtness B.; Harrington K.J.; Greil R.; Souli?res D.; Tahara M.; de Castro G.; Jr, Psyrri A.; Bast? N.; Neupane P.; Bratland ?.; Fuereder T.; Hughes B.G.M.; Mes?a R.; Ngamphaiboon N.; Rordorf T.; Wan Ishak W.Z.; RUEY-LONG HONG; Gonz?lez Mendoza R.; Roy A.; Zhang Y.; Gumuscu B.; Cheng J.D.; Jin F.; Rischin D.; Lerzo G.; Tatangelo M.; Varela M.; Zarba J.J.; Boyer M.; Gan H.; Gao B.; Hughes B.; Mallesara G.; Taylor A.; Burian M.; Barrios C.H.; de Castro Junior D.O.; Castro G.; Franke F.A.; Girotto G.; Lima I.P.F.; Nicolau U.R.; Pinto G.D.J.; Santos L.; Victorino A.-P.; Chua N.; Couture F.; Gregg R.; Hansen A.; Hilton J.; McCarthy J.; Soulieres D.; Ascui R.; Gonzalez P.; Villanueva L.; Torregroza M.; Zambrano A.; Holeckova P.; Kral Z.; Melichar B.; Prausova J.; Vosmik M.; Andersen M.; Gyldenkerne N.; Jurgens H.; Putnik K.; Reinikainen P.; Gruenwald V.; Laban S.; Aravantinos G.; Boukovinas I.; Georgoulias V.; Kwong D.; Al-Farhat Y.; Csoszi T.; Erfan J.; Horvai G.; Landherr L.; Remenar E.; Ruzsa A.; Szota J.; Billan S.; Gluck I.; Gutfeld O.; Popovtzer A.; Benasso M.; Bui S.; Ferrari V.; Licitra L.; Nole F.; Fujii T.; Fujimoto Y.; Hanai N.; Hara H.; Matsumoto K.; Mitsugi K.; Monden N.; Nakayama M.; Okami K.; Oridate N.; Shiga K.; Shimizu Y.; Sugasawa M.; Takahashi M.; Takahashi S.; Tanaka K.; Ueda T.; Yamaguchi H.; Yamazaki T.; Yasumatsu R.; Yokota T.; Yoshizaki T.; Kudaba I.; Stara Z.; Cheah S.K.; Aguilar Ponce J.; Gonzalez Mendoza R.; Hernandez Hernandez C.; Medina Soto F.; Buter J.; Hoeben A.; Oosting S.; Suijkerbuijk K.; Bratland A.; Brydoey M.; Alvarez R.; Mas L.; Caguioa P.; Querol J.; Regala E.E.; Tamayo M.B.; Villegas E.M.; Kawecki A.; Karpenko A.; Klochikhin A.; Smolin A.; Zarubenkov O.; Goh B.C.; Cohen G.; du Toit J.; Jordaan C.; Landers G.; Ruff P.; Szpak W.; Tabane N.; Brana I.; Iglesias Docampo L.; Lavernia J.; Mesia R.; Abel E.; Muratidu V.; Nielsen N.; Cristina V.; Rothschild S.; Wang H.-M.; Yang M.-H.; Yeh S.-P.; Yen C.-J.; Soparattanapaisarn N.; Sriuranpong V.; Aksoy S.; Cicin I.; Ekenel M.; Harputluoglu H.; Ozyilkan O.; Harrington K.; Agarwala S.; Ali H.; Alter R.; Anderson D.; Bruce J.; Campbell N.; Conde M.; Deeken J.; Edenfield W.; Feldman L.; Gaughan E.; Goueli B.; Halmos B.; Hegde U.; Hunis B.; Jotte R.; Karnad A.; Khan S.; Laudi N.; Laux D.; Martincic D.; McCune S.; McGaughey D.; Misiukiewicz K.; Mulford D.; Nadler E.; Nunnink J.; Ohr J.; O'Malley M.; Patson B.; Paul D.; Popa E.; Powell S.; Redman R.; Rella V.; Rocha Lima C.; Sivapiragasam A.; Su Y.; Sukari A.; Wong S.; Yilmaz E.; Yorio J. |
| 國立成功大學 |
2022-11 |
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
|
Tsai;Jeng-Shiuan;Wei;Sheng-Huan;Chen;Chian-Wei;Yang;Szu-Chun;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non?�small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
|
Papadimitrakopoulou V.;Raftopoulos H;Saraf S;Bachman R;Sequist L.V;Chih-Hsin Yang;Hauke R;Gubens M;Villaruz L.C;Patnaik A;Borghaei H;Gandhi L;Langer C.J;Stevenson J.P;Gadgeel S.M; Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial
|
Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
|
McRee A.J; Chia-Chi Lin; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang Y.-J.; Bang Y.-J.;Koshiji M;Juco J;Emancipator K;Lunceford J;Pathiraja K;Chia-Chi Lin;McRee A.J;Burtness B;Le D.T;Golan T;Eder J.P;Gupta S;Catenacci D;Geva R;Shankaran V;Chung H.C;Muro K; Muro K; Chung H.C; Shankaran V; Geva R; Catenacci D; Gupta S; Eder J.P; Golan T; Le D.T; Burtness B |
| 臺大學術典藏 |
2021-03-09T06:46:02Z |
Pembrolizumab for the treatment of advanced salivary gland carcinoma
|
Cohen R.B.;Delord J.-P.;Doi T.;Piha-Paul S.A.;Liu S.V.;Gilbert J.;Algazi A.P.;Damian S.;Ruey-Long Hong;Le Tourneau C.;Day D.;Varga A.;Elez E.;Wallmark J.;Saraf S.;Thanigaimani P.;Cheng J.;Keam B.; Cohen R.B.; Delord J.-P.; Doi T.; Piha-Paul S.A.; Liu S.V.; Gilbert J.; Algazi A.P.; Damian S.; RUEY-LONG HONG; Le Tourneau C.; Day D.; Varga A.; Elez E.; Wallmark J.; Saraf S.; Thanigaimani P.; Cheng J.; Keam B. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study
|
?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 國立臺灣大學 |
2016 |
Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
|
Zhu, A.; Knox, J.; Kudo, M.; Chan, S.; Finn, R.; Siegel, A.; Ma, J.; Watson, P. A.; Cheng, A-L.; 鄭安理 |
| 臺大學術典藏 |
2020-10-22T07:41:44Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
WEI-LI CHEN; Liu J.-H.; Yao M.; Hsiao C.-C.; Hsiao C.-C.;Yao M.;Liu J.-H.;Wei-Li Chen |
| 臺大學術典藏 |
2021-07-22T03:35:56Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; LIU JIA-HAU; Chen W.-L. |
| 臺大學術典藏 |
2021-01-05T03:34:30Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Chen W.-L.; Liu J.-H.; MING YAO; Hsiao C.-C. |
| 臺大學術典藏 |
2022-04-25T07:36:14Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; JIA-HAU LIU; Chen W.-L. |
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 Study
|
Rudin C.M.;Awad M.M.;Navarro A.;Gottfried M.;Peters S.;Csoszi T.;Cheema P.K.;Rodriguez-Abreu D.;Wollner M.;Chih-Hsin Yang;Mazieres J.;Orlandi F.J.;Luft A.;G?M?? M.;Kato T.;Kalemkerian G.P.;Luo Y.;Ebiana V.;Pietanza M.C.;Kim H.R.;Keynote-604 Investigators; Rudin C.M.; Awad M.M.; Navarro A.; Gottfried M.; Peters S.; Csoszi T.; Cheema P.K.; Rodriguez-Abreu D.; Wollner M.; CHIH-HSIN YANG; Mazieres J.; Orlandi F.J.; Luft A.; G?m?? M.; Kato T.; Kalemkerian G.P.; Luo Y.; Ebiana V.; Pietanza M.C.; Kim H.R.; KEYNOTE-604 Investigators |
| 臺大學術典藏 |
2021-04-26T08:05:25Z |
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|
Cortes J.; Cescon D.W.; Rugo H.S.; Nowecki Z.; Im S.-A.; Yusof M.M.; Gallardo C.; Lipatov O.; Barrios C.H.; Holgado E.; Iwata H.; Masuda N.; Otero M.T.; Gokmen E.; Loi S.; Guo Z.; Zhao J.; Aktan G.; Karantza V.; Schmid P.; Luis F.; Gonzalo G.A.; Diego K.; Ruben K.; Matias M.; Mirta V.; Sally B.-H.; Stephen B.; Philip C.; Sherene L.; Dhanusha S.; Andrea G.; Donatienne T.; Carlos B.; Leandro B.; Fabiano C.; Ruffo D.F.J.; Roberto H.; Domicio Carvalho L.; Fernando Cezar Toniazzi L.; Roberto Odebrecht R.; Antonio Orlando S.N.; Felipe S.; David C.; Danielle C.; Cristiano F.; Xinni S.; Joanne Y.; Alejandro A.; Carlos G.; Claudio S.; Cesar S.; Eduardo Y.; Alvaro G.D.; Jesus S.; Petra H.; Zdenek K.; Bohuslav M.; Katarina P.; Jana P.; Vesna G.; Erik J.; Jeanette J.; Soren L.; Tamas L.; Herve B.; Isabelle D.; Anthony G.; Anne-Claire H.-B.; Luis T.; Jens-Uwe B.; Peter F.; Dirk F.; Nadia H.; Jens H.; Anna K.F.D.S.; Christian K.; Sibylle L.; Diana L.; Tjoung-Won P.-S.; Raquel Von S.; Pauline W.; Louis C.; Ava K.; Kai Cheong Roger N.; Peter A.; Tibor C.; Zsuzsanna K.; Laszlo L.; Karoly M.; Gabor R.; John C.; Catherine K.; Seamus O.R.; Saverio C.; Antonietta D.A.; Enrico R.; Tomoyuki A.; Takaaki F.; Kenichi I.; Takashi I.; Yoshinori I.; Tsutomu I.; Hiroji I.; Yoshimasa K.; Koji M.; Yasuo M.; Hirofumi M.; Seigo N.; Naoki N.; Shoichiro O.; Akihiko O.; Yasuaki S.; Eiji S.; Masato T.; Yuko T.; Kenji T.; Koichiro T.; Junichiro W.; Naohito Y.; Yutaka Y.; Teruo Y.; Anita B.; Mastura M.Y.; Angel G.V.; Alejandro J.R.; Jorge M.R.; Flavia M.-V.; Jessica R.C.; Karin B.; Vivianne T.-H.; David P.; Ewa C.; Ewa N.-Z.; Zbigniew N.; Barbara R.; Joanna S.; Cezary S.; Rafal T.; Bogdan Z.; Alexander A.; Natalia F.; Oleg L.; Andrey M.; Vladimir M.; Guzel M.; Jin Hee A.; Seock-Ah I.; Keun Seok L.; Kwong Hwa P.; Yeon Hee P.; Begona B.D.L.H.; Javier C.; Josefina C.J.; Luis D.L.C.M.; Jose G.S.; Maria G.; Esther H.; Esther Z.A.; Chien-Ting L.; Mei-Ching L.; Chiun-Sheng H.; Chao-Jung T.; Ling-Ming T.; Cagatay A.; Gul B.; Irfan C.; Erhan G.; Seyda G.; Nil M.M.; Mustafa O.; Ozgur O.; Sinan Y.; Steve C.; Janine G.; Iain M.; Peter S.; Nicholas T.; Mark T.; Christopher T.; Duncan W.; Hryhoriy A.; Oleksandr B.; Igor B.; Oleksii K.; Olena K.; Hanna K.; Anna K.; Iurii L.; Alla N.; Natalya O.; Olga P.; Andrii R.; Sergii S.; Yaroslav S.; Dmytro T.; Grygorii U.; Ihor V.; Sibel B.; Madhu C.; Michael C.; Patrick C.; Scott C.; Jennifer D.; Keerthi G.; Jeffrey H.; Kent H.; William I.; Randa L.; Janice L.; Raul M.; Susan M.; Rita N.; Ira O.; Coral O.; Timothy P.; Amit P.; Brian P.; Hope R.; Irina R.; Michael S.; Robert S.; Michael S.; Laura S.; Bradley S.; Michaela T.; Frances V.-A.; KEYNOTE-355 Investigators; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 國立成功大學 |
2024-07-25 |
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
|
Boyer;Michael;Hui;Rina;Urban;Damien;Clingan;Philip;Su;Wu-Chou;Devaux;Celine;Gadgeel;Shirish;Garassino;Marina;Leopold;Lance;Daniel;Jeannie;Munteanu;Mihaela, C.;Samkari;Ayman;Luo;Yiwen;Abreu;Rodriguez, Delvys |
| 臺大學術典藏 |
2020-10-06T03:31:14Z |
Pembrolizumab-induced linear psoriasis
|
Huang P.-W.;Chia-Yu Chu; Huang P.-W.; CHIA-YU CHU |
| 臺大學術典藏 |
2021-11-10T05:59:11Z |
Pembrolizumab-induced linear psoriasis
|
PO-WEI HUANG; Chu C.-Y. |
| 國立臺灣大學 |
2015 |
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
|
Yang, James Chin-Hsin; Ahn, Myung-Ju; Nakagawa, Kazuhiko; Tamura, Tomohide; Barraclough, Helen; Enatsu, Sotaro; Cheng, Rebecca; Orlando, Mauro; 楊志新 |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2021-03-11T07:58:34Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
| 臺大學術典藏 |
2021-03-11T08:29:39Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
